Open AccessExtending the lymphoblastoid cell line model for drug combination pharmacogenomics
Author(s) -
Adrian Green,
Benedict Anchang,
Farida S. Akhtari,
David M. Reif,
Alison A. MotsingerReif
Publication year - 2021
Publication title -
pharmacogenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 91
eISSN - 1744-8042
pISSN - 1462-2416
DOI - 10.2217/pgs-2020-0160
Subject(s) - pharmacogenomics , computational biology , drug , pharmacogenetics , first line , bioinformatics , pharmacology , medicine , computer science , biology , genetics , genotype , gene
Combination drug therapies have become an integral part of precision oncology, and while evidence of clinical effectiveness continues to grow, the underlying mechanisms supporting synergy are poorly understood. Immortalized human lymphoblastoid cell lines (LCLs) have been proven as a particularly useful, scalable and low-cost model in pharmacogenetics research, and are suitable for elucidating the molecular mechanisms of synergistic combination therapies. In this review, we cover the advantages of LCLs in synergy pharmacogenomics and consider recent studies providing initial evidence of the utility of LCLs in synergy research. We also discuss several opportunities for LCL-based systems to address gaps in the research through the expansion of testing regimens, assessment of new drug classes and higher-order combinations, and utilization of integrated omics technologies.